Cynosure 532 nm laser delivery system receives FDA approval

March 11, 2015

Medical laser maker Cynosure has received FDA clearance for its 532 nm laser delivery system that works with the company's PicoSure picosecond aesthetic laser.

BioOptics World Editors

Medical laser maker Cynosure (NASDAQ:CYNO; Westford, MA) has received FDA clearance for its 532 nm laser delivery system that works with the company's PicoSure picosecond aesthetic laser to create a dual-wavelength laser system for removing tattoos of all colors in fewer treatments.

Related: Semiconductor diode laser advances enable medical applications

"The integration of the 532 nm wavelength into the PicoSure platform allows for more effective removal of red, orange, and yellow tattoo ink, which can now be cleared in fewer treatments," says Roy G. Geronemus, MD, director of the Laser & Skin Surgery Center of New York.

Cynosure expects to introduce the 532 nm laser delivery system for PicoSure at the American Academy of Dermatology (AAD)'s 2015 Annual Meeting, to take place March 20-24, 2015, in San Francisco, CA. Initial shipments are expected to begin by the end of the second quarter of 2015.

-----

Follow us on Twitter, 'like' us on Facebook, connect with us on Google+, and join our group on LinkedIn

About the Author

BioOptics World Editors

We edited the content of this article, which was contributed by outside sources, to fit our style and substance requirements. (Editor’s Note: BioOptics World has folded as a brand and is now part of Laser Focus World, effective in 2022.)